173 related articles for article (PubMed ID: 27146035)
1. Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012.
Bouvy JC; Huinink L; De Bruin ML
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1004-14. PubMed ID: 27146035
[TBL] [Abstract][Full Text] [Related]
2. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
3. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
[TBL] [Abstract][Full Text] [Related]
4. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
Mendes D; Alves C; Batel Marques F
Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
[TBL] [Abstract][Full Text] [Related]
5. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
6. Post-approval safety issues with innovative drugs: a European cohort study.
Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
[TBL] [Abstract][Full Text] [Related]
7. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
8. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Br J Clin Pharmacol; 2015 Oct; 80(4):716-26. PubMed ID: 25808713
[TBL] [Abstract][Full Text] [Related]
9. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
McNaughton R; Huet G; Shakir S
BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
[TBL] [Abstract][Full Text] [Related]
10. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
Blake KV; Prilla S; Accadebled S; Guimier M; Biscaro M; Persson I; Arlett P; Blackburn S; Fitt H
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1021-9. PubMed ID: 22039593
[TBL] [Abstract][Full Text] [Related]
11. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
Lane S; Lynn E; Shakir S
BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
[TBL] [Abstract][Full Text] [Related]
12. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
[TBL] [Abstract][Full Text] [Related]
13. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
[TBL] [Abstract][Full Text] [Related]
14. [How does a new medicine reach the patient?].
Visser BJ; Korevaar DA; Mokhles MM; Vermeer-Pragt W; de Boer A; Giezen TJ
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32779914
[TBL] [Abstract][Full Text] [Related]
15. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
16. Approvals of drugs with uncertain benefit-risk profiles in Europe.
Banzi R; Gerardi C; Bertele' V; Garattini S
Eur J Intern Med; 2015 Oct; 26(8):572-84. PubMed ID: 26342723
[TBL] [Abstract][Full Text] [Related]
17. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
Onakpoya IJ; Heneghan CJ; Aronson JK
Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
[TBL] [Abstract][Full Text] [Related]
18. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
[TBL] [Abstract][Full Text] [Related]
19. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]